> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# ARK Reports 8.36% Of Recursion's Class A Shares And Certifies A Passive Purpose
- URL: https://www.bullished.co/ark-reports-8-36-of-recursions-class-a-shares-and-certifies-a-passive-purpose-be55d2fa/
- Published: 2026-11-13T17:56:03.000Z
- Updated: 2026-11-13T17:56:03.000Z
- Description: The investment manager's September 30 position covered 44,745,024 shares in the AI drug developer.
- Author: Matteo Parrino
- Tags: SEC Filings, RXRX, Industry: Healthcare, Topic: Ownership & Activism

ARK Investment Management reported an [8.36% stake](https://www.sec.gov/Archives/edgar/data/0001697748/000110465926126833/xslSCHEDULE%5F13G%5FX01/primary%5Fdoc.xml?ref=bullished.co) in [Recursion Pharmaceuticals](https://www.bullished.co/tag/rxrx/), which uses artificial intelligence and automated labs to develop medicines, in an SEC passive ownership filing Friday. The position covered 44,745,024 Class A shares as of September 30, and ARK certified that its holdings were not intended to influence company control.

## ARK And Wood's Voting Authority

ARK reported sole authority to vote [42,796,887 shares](https://www.sec.gov/Archives/edgar/data/0001697748/000110465926126833/xslSCHEDULE%5F13G%5FX01/primary%5Fdoc.xml?ref=bullished.co), with another 548,854 shares under shared voting authority.

Catherine D. Wood, ARK's chief executive and chief investment officer, was a [joint reporting person](https://www.sec.gov/Archives/edgar/data/1697748/000110465926126833/tm2629184d9%5Fex1.htm?ref=bullished.co). Her reported shared voting authority covered 43,345,741 shares. ARK and Wood reported the same 44,745,024-share beneficial-ownership position; those entries describe the same holdings, not separate stakes to add together.

The passive certification says the securities were bought and held as part of ordinary business, without a purpose or effect of changing Recursion's control.

## An AI Drug-Discovery Holding

Recursion's business combines biological data generation, small-molecule design and clinical trial work through its Recursion Operating System. Its automated laboratories can conduct more than 2 million experiments a week, according to its annual report for the fiscal year ended December 31, 2025.

That report described five clinical programs and two preclinical programs spanning oncology and rare disease. Among them is REC-4881 for familial adenomatous polyposis.

Recursion also conducts partner-funded discovery work in oncology, neuroscience and immunology with Roche and Genentech, Sanofi, Bayer and Merck KGaA. It had received more than $500 million in upfront and milestone payments from partners to date, according to the annual report.

ARK's exchange-traded funds hold concentrated positions in small- and mid-cap companies, frequently taking its ownership above the 5% disclosure threshold. The manager has produced roughly 170 ownership schedules over two years.

Recursion's market capitalization was $2.1 billion in Friday trading as of 12:51 p.m. ET.

The ownership report measures ARK's September 30 position; Friday was the filing date.

Learn

- [13D Filing Requirements And Deadline, Shown With Real Filings →](https://www.bullished.co/learn/13d-filing-requirements/)  
A Schedule 13D is required when you own more than 5% of a public company's voting shares. See the deadline, contents and real filings from this week.
- [13D Vs 13G: What Each 5% Stake Filing Means And How To Read One →](https://www.bullished.co/learn/13d-vs-13g/)  
13D vs 13G: both report stakes above 5%, but 13G is the short passive form and 13D explains intent. See real BlackRock and Pictet filings read in plain English.

### Sources

- [SCHEDULE 13G/A — ARK Investment Management LLC re: Recursion Pharmaceuticals, Inc. (RXRX)](https://www.sec.gov/Archives/edgar/data/0001697748/000110465926126833/xslSCHEDULE%5F13G%5FX01/primary%5Fdoc.xml?ref=bullished.co) — SEC EDGAR
- [SCHEDULE 13G/A Exhibit 1 — EXHIBIT 1](https://www.sec.gov/Archives/edgar/data/1697748/000110465926126833/tm2629184d9%5Fex1.htm?ref=bullished.co) — SEC EDGAR

### More on Recursion Pharmaceuticals

- [State Street Holds 5.6% Of Recursion Pharmaceuticals On A Passive Basis](https://www.bullished.co/state-street-holds-5-6-of-recursion-pharmaceuticals-on-a-passive-basis-06ee1182/)
- [Recursion Says Oral FAP Drug Shrank Upper-Gut Polyps In 92% Of Patients](https://www.bullished.co/recursion-says-oral-fap-drug-shrank-upper-gut-polyps-in-92-of-patients-7658095a/)
- [Recursion Cuts Its Tempus Data Fee To $14.0 Million A Year, But Loses The Right To Walk Away](https://www.bullished.co/recursion-cuts-its-tempus-data-fee-to-14-0-million-a-year-but-loses-the-right-to-walk-away-d7bf91db/)

[All Recursion Pharmaceuticals (RXRX) coverage →](https://www.bullished.co/tag/rxrx/)